Israel Englander Amylyx Pharmaceuticals, Inc. Call Options Transaction History

Millennium Management LLC

5 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q1 2024 May 15, 2024	SELL	$2.71 - $19.57 $436,852 - $3.15 Million	-161,200 Reduced 80.12%	40,000 $113,000
Q4 2023 Feb 14, 2024	BUY	$12.07 - $18.46 $2.43 Million - $3.71 Million	201,200 New	201,200 $2.96 Million
Q1 2023 May 15, 2023	BUY	$27.71 - $40.93 $96,985 - $143,255	3,500 Added 13.21%	30,000 $880,000
Q4 2022 Feb 14, 2023	SELL	$29.75 - $39.26 $4.31 Million - $5.68 Million	-144,800 Reduced 84.53%	26,500 $979,000
Q3 2022 Nov 14, 2022	BUY	$17.15 - $30.92 $2.4 Million - $4.33 Million	140,000 Added 447.28%	171,300 $4.82 Million

127

44.4M

235K

530K

Ticker AMLX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,533,200
Market Cap $310M
Description
Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment...

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.